Month: August 2021

Heterologous prime-boost with KISIMA-TAA and VSV-GP-TAA induces long-term immunity To characterize the heterologous combination of KISIMA-TAA with VSV-GP-TAA oncolytic vaccine, we first investigated the schedule of administration using OVA. Priming with subcutaneous injection of KISIMA-OVA followed by intramuscular boost with VSV-GP-OVA elicited higher proportion (frequency and number) of circulating OVA-specific CD8+ T cells compared to
0 Comments
Supply chain disruptions during the coronavirus pandemic highlighted a key vulnerability for countries like the United States, which have come to rely on overseas sources for certain medicines and the raw materials to produce them. So on Monday, when a penicillin plant in Tennessee reopened after slipping into bankruptcy a year ago, officials were sure to highlight the significance of
0 Comments
Results from the EMPEROR-Preserved Phase III trial have shown that Jardiance (empagliflozin) demonstrated a 21% relative risk reduction of cardiovascular death or hospitalisation for heart failure in adults with heart failure with preserved ejection fraction (HFpEF). The data, presented at the European Society of Cardiology (ESC) Congress on 27 August 2021, also showed that the
0 Comments
Since the COVID-19 pandemic reached the United States in early 2020, scientists have struggled to find laboratory models of SARS-CoV-2 infection, the respiratory virus that causes COVID-19. Animal models fell short; attempts to grow adult human lungs have historically failed because not all of the cell types survived. Undaunted, stem cell scientists, cell biologists, infectious
0 Comments
Incyte and MorphoSys’ antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative to expensive and cumbersome CAR-T therapies for patients with certain types of lymphoma. The European Commission has approved tafasitamab in combination with Bristol-Myers Squibb’s Revlimid (lenalidomide), followed by the antibody on its own, for the treatment of
0 Comments
New guidance from NICE has rejected a combination regimen based on Johnson & Johnson’s Darzalex for a group of previously-untreated patients with multiple myeloma, a type of bone marrow cancer. The draft document covers the use of Darzalex (daratumumab) as an add-on to standard induction treatment with Takeda’s Velcade (bortezomib) plus thalidomide and dexamethasone given
0 Comments
Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. His second column addresses the vital importance of prioritisation. There used to be times when every single task seemed important. Naturally. I’m a perfectionist
0 Comments
The data is now in from the EMPEROR-Preserved study of Boehringer Ingelheim and Eli Lilly’s Jardiance in heart failure with preserved ejection fraction (HFpEF), and suggest the drug performs better than Novartis’ Entresto – currently the only approved option for these patients. SGLT2 inhibitor Jardiance (empagliflozin) reduced a composite of cardiovascular (CV) death or hospitalisations
0 Comments
Strains and growth conditions E. coli NEB 10-beta (NEB10β) was used for all plasmid cloning and protein production. For all cloning, E. coli strains were cultured in Terrific Broth (TB) containing 24 g/L yeast extract, 20 g/L tryptone, 0.4% v/v glycerol, 17 mM KH2PO4, and 72 mM K2HPO4 at 37 °C with appropriate antibiotics (50 µg/mL kanamycin). M9 glucose medium with
0 Comments
Voxzogo is just one of two medicines BioMarin executives think could completely transform the biotech. And now, with an approval in Europe, the achondroplasia treatment may be well on its way.  The European Commission on Friday approved the once-daily injection to treat achondroplasia, the most common form of skeletal dysplasia that leads to dwarfism, BioMarin
0 Comments
The National Institute for Health and Care Excellence (NICE) has published draft guidance stating that it does not recommend Janssen’s Darzalex (daratumumab) plus bortezomib, thalidomide and dexamethasone, as a treatment option for untreated multiple myeloma in adults who are eligible for an autologous stem cell transplant. Currently, most individuals with this condition receive a combination
0 Comments
The ongoing coronavirus disease 2019 (COVID-19) pandemic, which is brought about by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses a serious threat to human health worldwide. Previous research has indicated higher rates of adverse outcomes in pregnant women who are infected with SARS-CoV-2. Recently, a new study published on the pre-print server bioRxiv*
0 Comments
The spectrum of special purpose acquisition company mergers encompasses all deal sizes. While multibillion-dollar mergers have defined the space in 2021, Revelation Biosciences is joining with Petra Acquisition to create a Nasdaq-listed company with the relatively Lilliputian enterprise value of $128 million.  San Diego-based Revelation will pocket $73 million through the merger. Revelation will use
0 Comments
Collection of samples Figure 1 showing topo geographical view of the sample collection site, Kallukuttai Lake, located near Taramani Railway Station, Chennai City, Tamil Nadu, India with longitude and latitude positions 12°58′41.70″ North and 80°14′08.57″ East respectively. The site was chosen based on the dumping of domestic wastes along the freshwater bodies due to rapid urbanization.
0 Comments
When Bayer unveiled early-stage results from a finerenone trial at the European Society of Cardiology Congress in 2014, the company declared it was going all in on the kidney disease drug.  Later that year, Bayer began a trio of phase 3 trials so exhaustive that data are still being released seven years later. Fast forward to Saturday at ESC
0 Comments
An investigational drug called NXP800, discovered at the Cancer Research UK Cancer Therapeutics Unit at London’s Institute of Cancer Research (ICR), is to enter Phase I clinical trials in patients with advanced cancers. The Phase I study will begin later this year and is being funded by oncology-focused biopharmaceutical company Nuvectis Pharma. The investigational oral
0 Comments
Announcing a new article publication for Zoonoses journal. In this article the authors Jianqin Liang, Guizeng Liu, Shuzhuang Yu, Yang Yang, Yanchun Li, Hongli Tian, Zhe Chen and Wenping Gong The Eighth Medical Center of PLA General Hospital, Beijing, China and Nanpi County People’s Hospital, Hebei, China discuss dynamic changes in chest CT images over
0 Comments